The BRCA2-EMSY connection: implications for breast and ovarian tumorigenesis.
In this issue, Hughes-Davies et al. describe a novel gene product, EMSY, which suppresses the transactivational activity of BRCA2. EMSY is located within an amplicon in sporadic breast and ovarian cancers, suggesting that its overexpression may mimic the effects of BRCA2 inactivation. The implications for BRCA2 function are discussed.
Haber
Daniel A
DA
Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
D024682:BRCA2 Protein / Q000235:genetics* / Q000378:metabolism; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism; D002277:Carcinoma / Q000235:genetics* / Q000378:metabolism; D005260:Female; D005809:Genes, Regulator / Q000235:genetics; D006801:Humans; D009154:Mutation / Q000235:genetics; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000378:metabolism; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000302:isolation & purification*
D024682:BRCA2 Protein; D025521:Tumor Suppressor Proteins